Guide
EU MDR and UKCA compliance for medical devices
Since Brexit, placing a device on the European and British markets means satisfying two related but separate regimes. Planning them together is far cheaper than discovering the differences after the technical file is written.
What EU MDR expects
The EU Medical Device Regulation raised the bar on clinical evidence, post-market surveillance, and traceability compared with the directive it replaced. For most manufacturers the practical consequences are a heavier technical documentation package, a stronger clinical evaluation, and an ongoing post-market obligation rather than a one-time submission.
- Technical documentation aligned to the regulation's annexes
- Clinical evaluation supported by sufficient clinical data for the device and its claims
- Post-market surveillance and periodic safety update reporting proportional to risk class
- UDI assignment and EUDAMED registration obligations
- A quality management system, typically demonstrated through ISO 13485
- An authorised representative in the EU for manufacturers based elsewhere
How UKCA differs
Great Britain operates its own conformity marking and its own approved body system, with a separate registration with the MHRA and a UK Responsible Person for non-UK manufacturers. Northern Ireland follows different arrangements again.
Transitional acceptance of CE-marked devices in Great Britain has been extended more than once and the UK regime continues to evolve, so the applicable deadlines should be confirmed against current MHRA guidance rather than assumed.
Plan the evidence once, use it twice
Most of the underlying evidence — risk management file, clinical evaluation, biocompatibility, usability, software lifecycle documentation — serves both regimes. What differs is packaging, registration, representation, and some labelling requirements.
The expensive mistake is generating evidence for one jurisdiction, then finding a second requires an additional endpoint or a differently framed clinical evaluation. Mapping the requirements side by side before a study protocol is finalised avoids that.
MedTech Compass handles the MedTech regulatory triage — comparing EU MDR and UKCA routes against global FDA pathways for the same device, with multi-dimensional market scoring across 25+ markets. MedTech Copilot then works as AI medical device documentation and MedTech QMS software, keeping automated design history files, risk analysis, and evidence summaries structured and audit-ready as the programme progresses.
Frequently asked questions
- Can a CE-marked device be sold in Great Britain?
- Great Britain has accepted CE-marked devices under transitional arrangements that have been extended more than once. Because the dates have changed, confirm the current position in MHRA guidance for your device class before planning around it.
- Do I need both an EU Authorised Representative and a UK Responsible Person?
- A manufacturer based outside the EU needs an EU authorised representative to place devices on the EU market, and a manufacturer based outside the UK needs a UK Responsible Person for the UK market. They are separate roles and can be separate organisations.
- Is ISO 13485 certification mandatory?
- The regulation requires an appropriate quality management system rather than naming the standard, but ISO 13485 certification is the route almost all manufacturers take to demonstrate it, and notified bodies expect it in practice.